Scarica l'app Stockscreener
19.16
2.24%
0.42
Dopo l'orario di chiusura:
19.19
0.03
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
GCM Grosvenor (NASDAQ:GCMGW) Trading Up 1.1% – Should You Buy? - Defense World
Encore Capital Group (NASDAQ:ECPG) & Manhattan Bridge Capital (NASDAQ:LOAN) Critical Review - Defense World
Obesity Clinical Trials, Companies, Therapeutic Assessment, - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Private Advisor Group LLC Buys 489 Shares of Quanta Services, Inc. (NYSE:PWR) - Defense World
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN) - The Globe and Mail
Easterly Investment Partners LLC Has $23.78 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM) - Defense World
Microchip Technology Incorporated (NASDAQ:MCHP) Holdings Decreased by Private Advisor Group LLC - Defense World
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Shilanski & Associates Inc. - Defense World
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - AOL.com
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
BMO Nasdaq 100 Equity Hedged to CAD Index ETF (TSE:ZQQ) Trading 0.8% Higher – Time to Buy? - Defense World
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Business Wire
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS) - The Globe and Mail
H.C. Wainwright Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Principal Financial Group Inc. Has $14.24 Million Stock Holdings in Universal Display Corporation (NASDAQ:OLED) - Defense World
Principal Financial Group Inc. Decreases Stock Holdings in Shift4 Payments, Inc. (NYSE:FOUR) - Defense World
Principal Financial Group Inc. Sells 11,305 Shares of Nova Ltd. (NASDAQ:NVMI) - Defense World
Principal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) - Defense World
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Amedisys (AMED) and Xoma (XOMA) - The Globe and Mail
Structure in partnering talks for GLP-1 pill as mid-stage readout nears - Endpoints News
Scage Future shares rise 2.16% in after-hours after extending business merger agreement deadline and establishing ADR facility. - AInvest
Structure Therapeutics Holds 2025 Annual Shareholders Meeting - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Receives “Market Outperform” Rating from JMP Securities - Defense World
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure - Business Wire
Breakthrough Oral Obesity Drug Matches Injectable Results, Shows Added Benefits With Wegovy in Trial Data - Stock Titan
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - AOL.com
Data-Based Insights About Structure Therapeutics Inc ADR (GPCR) - Stocksregister
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Comments on GPCR FY2026 Earnings - Defense World
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):